Literature DB >> 12597915

Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis.

N D Brewis1, A Phelan, N Normand, E Choolun, P O'Hare.   

Abstract

Previously we showed that addition of purified VP22, a structural protein of herpes simplex virus, to short oligonucleotides (ODN) induced the spontaneous assembly of novel particles incorporating both protein and ODN. These particles were not toxic, entered cells, and resided stably in the cytoplasm. Surprisingly the particles could be activated by light in a regulated synchronous manner to release ODN and protein to the cell cytosol and nuclei. Here we construct a fusion protein containing a short peptide from the proapoptotic BH3 domain family member Bak. The BH3-VP22 protein was recruited into particles that entered cells and remained stable in the cytoplasm without toxicity. Light activation rapidly disrupted the particles, a process captured in living cells by time-lapse microscopy, and this synchronized regulated release resulted in subsequent cell death by apoptosis. In control experiments, particles containing a mutant BH3 peptide, although indistinguishable in cell uptake and regulated release, showed no apoptotic effect. Regulated release of VP22-based particles may find application in mechanistic analysis of apoptotic pathways, in cell-based screening assays both of peptides and of oligonucleotides, or as therapeutic agents incorporating specific additional components.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12597915     DOI: 10.1016/s1525-0016(02)00054-0

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  4 in total

1.  Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal Apoptin-VP22 fusion proteins.

Authors:  Saskia A Rutjes; Piter J Bosma; Jennifer L Rohn; Mathieu H M Noteborn; John G Wesseling
Journal:  J Mol Med (Berl)       Date:  2003-07-16       Impact factor: 4.599

2.  Gene transfer: Bax to the future for cancer therapy.

Authors:  N R Lemoine; I A McNeish
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

Review 3.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

Review 4.  Tumor penetrating peptides for improved drug delivery.

Authors:  Erkki Ruoslahti
Journal:  Adv Drug Deliv Rev       Date:  2016-04-01       Impact factor: 15.470

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.